R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 373 ILS -0.79% Market Closed
Market Cap: 162.5m ILS
Have any thoughts about
Rekah Pharmaceutical Industry Ltd?
Write Note

Intrinsic Value

The intrinsic value of one REKA stock under the Base Case scenario is 2 330.53 ILS. Compared to the current market price of 1 373 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 41%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

REKA Intrinsic Value
2 330.53 ILS
Undervaluation 41%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation Backtest
Rekah Pharmaceutical Industry Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for REKA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about REKA?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Rekah Pharmaceutical Industry Ltd

Provide an overview of the primary business activities
of Rekah Pharmaceutical Industry Ltd.

What unique competitive advantages
does Rekah Pharmaceutical Industry Ltd hold over its rivals?

What risks and challenges
does Rekah Pharmaceutical Industry Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Rekah Pharmaceutical Industry Ltd.

Provide P/S
for Rekah Pharmaceutical Industry Ltd.

Provide P/E
for Rekah Pharmaceutical Industry Ltd.

Provide P/OCF
for Rekah Pharmaceutical Industry Ltd.

Provide P/FCFE
for Rekah Pharmaceutical Industry Ltd.

Provide P/B
for Rekah Pharmaceutical Industry Ltd.

Provide EV/S
for Rekah Pharmaceutical Industry Ltd.

Provide EV/GP
for Rekah Pharmaceutical Industry Ltd.

Provide EV/EBITDA
for Rekah Pharmaceutical Industry Ltd.

Provide EV/EBIT
for Rekah Pharmaceutical Industry Ltd.

Provide EV/OCF
for Rekah Pharmaceutical Industry Ltd.

Provide EV/FCFF
for Rekah Pharmaceutical Industry Ltd.

Provide EV/IC
for Rekah Pharmaceutical Industry Ltd.

Compare the intrinsic valuations
of Rekah Pharmaceutical Industry Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Rekah Pharmaceutical Industry Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Rekah Pharmaceutical Industry Ltd compared to its peers.

Compare the P/E ratios
of Rekah Pharmaceutical Industry Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Rekah Pharmaceutical Industry Ltd with its peers.

Analyze the financial leverage
of Rekah Pharmaceutical Industry Ltd compared to its main competitors.

Show all profitability ratios
for Rekah Pharmaceutical Industry Ltd.

Provide ROE
for Rekah Pharmaceutical Industry Ltd.

Provide ROA
for Rekah Pharmaceutical Industry Ltd.

Provide ROIC
for Rekah Pharmaceutical Industry Ltd.

Provide ROCE
for Rekah Pharmaceutical Industry Ltd.

Provide Gross Margin
for Rekah Pharmaceutical Industry Ltd.

Provide Operating Margin
for Rekah Pharmaceutical Industry Ltd.

Provide Net Margin
for Rekah Pharmaceutical Industry Ltd.

Provide FCF Margin
for Rekah Pharmaceutical Industry Ltd.

Show all solvency ratios
for Rekah Pharmaceutical Industry Ltd.

Provide D/E Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide D/A Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Interest Coverage Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Altman Z-Score Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Quick Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Current Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Cash Ratio
for Rekah Pharmaceutical Industry Ltd.

What is the historical Revenue growth
over the last 5 years for Rekah Pharmaceutical Industry Ltd?

What is the historical Net Income growth
over the last 5 years for Rekah Pharmaceutical Industry Ltd?

What is the current Free Cash Flow
of Rekah Pharmaceutical Industry Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Rekah Pharmaceutical Industry Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Rekah Pharmaceutical Industry Ltd

Current Assets 225m
Cash & Short-Term Investments 5.4m
Receivables 120.2m
Other Current Assets 99.4m
Non-Current Assets 226.8m
Long-Term Investments 1.2m
PP&E 148.3m
Intangibles 63.7m
Other Non-Current Assets 13.7m
Current Liabilities 151m
Accounts Payable 111.8m
Short-Term Debt 22.4m
Other Current Liabilities 16.8m
Non-Current Liabilities 131.7m
Long-Term Debt 101.8m
Other Non-Current Liabilities 29.9m
Efficiency

Earnings Waterfall
Rekah Pharmaceutical Industry Ltd

Revenue
324.4m ILS
Cost of Revenue
-248.9m ILS
Gross Profit
75.4m ILS
Operating Expenses
-57.3m ILS
Operating Income
18.1m ILS
Other Expenses
-11.3m ILS
Net Income
6.8m ILS

Free Cash Flow Analysis
Rekah Pharmaceutical Industry Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

REKA Profitability Score
Profitability Due Diligence

Rekah Pharmaceutical Industry Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
45/100
Profitability
Score

Rekah Pharmaceutical Industry Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

REKA Solvency Score
Solvency Due Diligence

Rekah Pharmaceutical Industry Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
34/100
Solvency
Score

Rekah Pharmaceutical Industry Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REKA Price Targets Summary
Rekah Pharmaceutical Industry Ltd

There are no price targets for REKA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for REKA?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for REKA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Rekah Pharmaceutical Industry Ltd

Country

Israel

Industry

Pharmaceuticals

Market Cap

162.5m ILS

Dividend Yield

0%

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.

Contact

Holon
30 Hamelach Street, Ezor Hata`Asiya, T.D. 25
+97235581233
www.rekah.co.il

IPO

1995-12-14

Employees

399

Officers

CEO & Director
Mr. Mordechai Elgrabli
Director of Industrial Division & Director
Ms. Georgette Elgrabli
Chief Executive Officer of Ophir Shalpharm
Mr. Jacob Elgrably
Chief Executive Officer - Fresh of Life Pharma Ltd.
Mr. Nir Sella
Director of Operations
Mr. Meir Melumad
Deputy CEO & Director of Business Development
Mr. Yuval Elgrabli
Show More
Chief Executive Officer of Ophir & Shalpharm Ltd
Mr. Yaakov Elgrabli
Show Less

See Also

Discover More
What is the Intrinsic Value of one REKA stock?

The intrinsic value of one REKA stock under the Base Case scenario is 2 330.53 ILS.

Is REKA stock undervalued or overvalued?

Compared to the current market price of 1 373 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 41%.

Back to Top